KrebsâHenseleit solution, developed by Hans Krebs and Kurt Henseleit, is a solution containing sodium (Na), potassium (K), chloride (Cl), calcium (Ca), magnesium sulfate (MgSO4), bicarbonate (HCO3), phosphate (PO4), glucose, [1] and sometimes supplemented with albumin, and tromethamine (THAM). [2]
It has been used experimentally, for instance to study arteries ex vivo, [3] in Langendorff heart preparations, [4] and during isolated muscle testing of mammalian skeletal muscles.
- ^ "Krebs-Henseleit (KH) Buffer". Cold Spring Harbor Protocols. 2006: pdb.rec581. 1 June 2006. doi: 10.1101/pdb.rec581. Retrieved 6 May 2021.
- ^ curehunter.com > KrebsâHenseleit solution Retrieved on April 14, 2010
- ^ Quan A, Leung SW, Lao TT, Man RY (December 2003). "5-hydroxytryptamine and thromboxane A2 as physiologic mediators of human umbilical artery closure". J. Soc. Gynecol. Investig. 10 (8): 490â5. doi: 10.1016/S1071-5576(03)00149-7. PMID 14662162.
- ^ Bailey, Leslie E.; Ong, Seok D. (August 1978). "Krebs-Henseleit solution as a physiological buffer in perfused and superfused preparations". Journal of Pharmacological Methods. 1 (2): 171â175. doi: 10.1016/0160-5402(78)90022-0. Retrieved 6 May 2021.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
KrebsâHenseleit solution, developed by Hans Krebs and Kurt Henseleit, is a solution containing sodium (Na), potassium (K), chloride (Cl), calcium (Ca), magnesium sulfate (MgSO4), bicarbonate (HCO3), phosphate (PO4), glucose, [1] and sometimes supplemented with albumin, and tromethamine (THAM). [2]
It has been used experimentally, for instance to study arteries ex vivo, [3] in Langendorff heart preparations, [4] and during isolated muscle testing of mammalian skeletal muscles.
- ^ "Krebs-Henseleit (KH) Buffer". Cold Spring Harbor Protocols. 2006: pdb.rec581. 1 June 2006. doi: 10.1101/pdb.rec581. Retrieved 6 May 2021.
- ^ curehunter.com > KrebsâHenseleit solution Retrieved on April 14, 2010
- ^ Quan A, Leung SW, Lao TT, Man RY (December 2003). "5-hydroxytryptamine and thromboxane A2 as physiologic mediators of human umbilical artery closure". J. Soc. Gynecol. Investig. 10 (8): 490â5. doi: 10.1016/S1071-5576(03)00149-7. PMID 14662162.
- ^ Bailey, Leslie E.; Ong, Seok D. (August 1978). "Krebs-Henseleit solution as a physiological buffer in perfused and superfused preparations". Journal of Pharmacological Methods. 1 (2): 171â175. doi: 10.1016/0160-5402(78)90022-0. Retrieved 6 May 2021.
|
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |